Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840752 | 0.93 | TBK1 (0.44) | TBK1IKBKECDK2AURKBKDM4E | |
| Trifluoroacetic Acid SCHEMBL4845728 | 0.89 | LMNA (0.40) | ALDH1A1CHEK2KDM4EMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL4844409 | 0.88 | ALDH1A1 (0.46) | TBK1ALDH1A1AURKBCHEK2KDM4E | |
| Trifluoroacetic Acid SCHEMBL4839422 | 0.84 | KDM4E (0.43) | ALDH1A1CHEK2KDM4EMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL4843340 | 0.84 | CHEK2 (0.40) | ALDH1A1CHEK2KDM4EMEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL4843958 | 0.83 | CHEK2 (0.44) | TBK1IKBKEALDH1A1CDK2AURKB | |
| Trifluoroacetic Acid SCHEMBL4842116 | 0.83 | CHEK2 (0.53) | TBK1IKBKECDK2AURKBCHEK2 | |
| SCHEMBL4842267 | 0.82 | CYP3A4 (0.43) | TBK1ALDH1A1MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL4835045 | 0.81 | CHEK2 (0.46) | TBK1IKBKECDK2AURKBCHEK2 | |
| Trifluoroacetic Acid SCHEMBL4837609 | 0.81 | TRPV3 (0.39) | TBK1ALDH1A1AURKBCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | TBK1 1029/4885IKBKE 95/4885ALDH1A1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.